Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes.

Citation data:

Expert opinion on therapeutic targets, ISSN: 1744-7631, Vol: 20, Issue: 6, Page: 677-87

Publication Year:
2016
Captures 2
Readers 2
Social Media 1
Tweets 1
Citations 3
Citation Indexes 3
Repository URL:
http://scholarworks.unist.ac.kr/handle/201301/18014
PMID:
26610046
DOI:
10.1517/14728222.2016.1125885
Author(s):
Mongiorgi, Sara; Finelli, Carlo; Yang, Young Ryoul; Clissa, Cristina; McCubrey, James A.; Billi , Anna Maria; Manzoli, Lucia; Suh, Pann-Ghill; Cocco, Lucio; Follo, Marilde Y.
Publisher(s):
Informa Healthcare; INFORMA HEALTHCARE
Tags:
Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics; Myelodysplastic syndromes; nuclear inositides; PI-PLCbeta1; PI-PLCgamma1; PI3K/Akt/mTOR
Most Recent Tweet View All Tweets
review description
Nuclear inositide signaling pathways specifically regulate cell proliferation and differentiation. Interestingly, the modulation of nuclear inositides in hematological malignancies can differentially affect erythropoiesis or myelopoiesis. This is particularly important in patients with myelodysplastic syndromes (MDS), who show both defective erythroid and myeloid differentiation, as well as an increased risk of evolution into acute myeloid leukemia (AML).